Max Portfolio Pct.
Check
Valuation
Check
Stock Quality:
Max Portfolio Pct.
Check
Valuation
Check
MACK Price Action
MACK RSI Chart
MACK Valuation
MACK Price/Sales (Trailing)
The Good, Bad and Ugly
Growth
Profitability
Size
Dilution Risk
Balance Sheet
Momentum
Funds Popularity
Insider Trading
MACK Fundamentals
MACK Revenue
MACK Earnings
MACK Profitability
MACK Investor Care
Revenue & Growth
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 0 | 2.8M | 3.8M | 4.9M |
| 2017 | 0 | 96.7M | 49.2M | 1.7M |
| 2016 | 95.7M | 92.8M | 104.5M | 144.3M |
| 2015 | 104.6M | 113.3M | 101.7M | 89.3M |
| 2014 | 46.2M | 55.5M | 76.7M | 102.8M |
| 2013 | 52.2M | 58.6M | 54.2M | 47.8M |
| 2012 | 39.1M | 44.6M | 47.3M | 48.9M |
| 2011 | 23.8M | 27.3M | 30.7M | 34.2M |
| 2010 | 0 | 0 | 0 | 20.3M |
Get all data in R, Python etc through our Historical Stock Data APIs
Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.
| CEO | Mr. Gary L. Crocker M.B.A., MBA |
|---|---|
| WEBSITE | merrimack.com |
| SECTOR | Healthcare |
| INDUSTRY | Biotechnology |
